Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy
Posted inClinical Updates news Oncology

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patients ineligible for cystectomy.
Evaluating the Impact of Multicancer Early-Detection Blood Tests on Late-Stage Cancer Diagnosis: Insights from a Large Randomized Trial
Posted innews Oncology Public Health

Evaluating the Impact of Multicancer Early-Detection Blood Tests on Late-Stage Cancer Diagnosis: Insights from a Large Randomized Trial

A large randomized trial assessing whether adding a blood-based multicancer early-detection test to usual care reduces late-stage cancer diagnoses found no significant difference in stage III or IV cancers but observed a trend toward fewer stage IV cancers after three screening rounds.
Enhancing Precision in Minimally Invasive Liver Resection for Colorectal Metastases Using Indocyanine Green Fluorescence: Insights from the SICE Liver ICG Study
Posted inGeneral Surgery news Oncology

Enhancing Precision in Minimally Invasive Liver Resection for Colorectal Metastases Using Indocyanine Green Fluorescence: Insights from the SICE Liver ICG Study

The SICE Liver ICG study demonstrated that indocyanine green fluorescence imaging significantly improves detection and margin assessment during minimally invasive, parenchymal-sparing liver resections for colorectal metastases, supporting more precise surgery and better oncologic outcomes.
Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers
Posted innews OB/GYN & Women's Health Oncology

Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers

This phase 1/2 study evaluates farletuzumab ecteribulin, a folate receptor alpha-targeting ADC, showing that fractionated dosing reduces interstitial lung disease risk and demonstrates preliminary antitumor activity in advanced ovarian, endometrial, triple-negative breast, and lung cancers.